🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Hunan Cancer Hospital clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Hunan Cancer Hospital as lead sponsor. Synced 26 Sep 2026
20Current trials
17Recruiting now
11Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Hunan Cancer Hospital is the lead sponsor of 20 current clinical trials in our China register. 17 are recruiting patients now. The most common phase is Observational. The drugs named most often in its trials are Utidelone, Anastrozole, Exemestane and Cadonilimab. The most-studied condition is Breast Cancer.

ClinicalTrials.gov trials by status

  • Recruiting1785%
  • Not yet open210%
  • Active, closed15%

Trials by phase

  • Observational840%
  • Phase 2630%
  • Not applicable210%
  • Phase 1/215%
  • Phase 115%
  • Phase 415%
  • Phase 315%
01

Clinical trials sponsored by Hunan Cancer Hospital

20 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcinoma
NCT07314216 · ClinicalTrials.gov ↗ · NSCLC (Non-small Cell Lung Carcinoma), Stage III, EGFR Uncommon Mutations
Phase 2 Recruiting 2026-06 China
Precision Navigation to Improve Community Cancer Screening Participation
NCT07676383 · ClinicalTrials.gov ↗ · Cancer Screening, Lung Cancer, Breast Cancer
Not applicable Recruiting 2026-08 China
18F-FAPI-04 PET/CT and PET/MR in Patients With Various Types of Malignant Tumors
NCT06557590 · ClinicalTrials.gov ↗ · Cancer, FAP
Observational Recruiting 2024-01 China
Utidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant Therapy
NCT06385990 · ClinicalTrials.gov ↗ · Triple Negative Breast Neoplasms
Drug: Utidelone
Phase 2 Recruiting 2024-03 China
Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma
NCT06406634 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma
Phase 2 Recruiting 2024-05 China
Anlotinib-based Combination Therapy in Patients with Hormone Receptor-positive(HR+) Metastatic Breast Cancer(MBC) .
NCT06734533 · ClinicalTrials.gov ↗ · HR+ Breast Cancer
Observational Recruiting 2024-12 China
UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases
NCT05535413 · ClinicalTrials.gov ↗ · Metastatic HER2 Negative Breast Carcinoma, Brain Metastases, Capecitabine
Phase 1/2 Recruiting 2023-01 China
Preliminary Study on the Diagnostic Value Comparison of 18F-FAPI-04 PET/CT and PET/MR in Gastric Cancer
NCT06543108 · ClinicalTrials.gov ↗ · Gastric Cancer
Observational Recruiting 2024-01 China
Sequencing-based Counting of Plasma Epstein-Barr Virus DNA in Non-metastatic Nasopharyngeal Carcinoma
NCT06321939 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma, Herpesvirus 4, Human
Observational Recruiting 2024-01 China
LDRT and Chemoimmunotherapy in NPC With Liver Metastasis
NCT06788002 · ClinicalTrials.gov ↗ · Nasopharyngeal Cancinoma (NPC)
Phase 2 Recruiting 2025-01 China
A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC
NCT05940532 · ClinicalTrials.gov ↗ · Carcinoma, Non-Small-Cell Lung
Phase 2 Recruiting 2023-06 China
Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd
NCT07073755 · ClinicalTrials.gov ↗ · Metastatic Breast Cancer, Drug Resistance, Hormone Receptor-Positive Breast Cancer
Observational Recruiting 2023-01 China
Shenqi Fuwei Mixture Combined With Chemotherapy Neoadjuvant Therapy for Locally Advanced Gastric Cancer
NCT07098026 · ClinicalTrials.gov ↗ · Gastric Cancer, Adenocarcinoma
Not applicable Recruiting 2025-05 China
Real-World Study on CDK4/6 Inhibitors Combined With Endocrine Therapy and Subsequent Treatment in HR+/HER2- MBC.
NCT06033287 · ClinicalTrials.gov ↗ · Breast Cancer, Endocrine Therapy, CDK4/6 Inhibitors
Observational Recruiting 2023-01 China
Bone Marrow Protective Effect of Trilaciclib in Postoperative CCRT for LA-HNSCC
NCT06752798 · ClinicalTrials.gov ↗ · Head and Neck Cancer Squamous Cell Carcinoma
Phase 2 Recruiting 2024-12 China
Evaluation of Treatment Efficacy by Circulating Tumor Cell Phenotype Surveillance in Breast Cancer Patients
NCT05326295 · ClinicalTrials.gov ↗ · Breast Neoplasms, Neoplastic Cells, Circulating, Chemotherapy Effect
Observational Recruiting 2019-03 China
Immunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer
NCT06840704 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer, Small Cell Lung Cancer
Phase 3 Recruiting 2025-02 China
A Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 Inhibitors
NCT07163481 · ClinicalTrials.gov ↗ · Stage IV (Metastatic) Breast Cancer
Phase 1 Not yet open 2025-10 China
Rucaparib Monoclonal Antibody for Lorlatinib-Induced Hypercholesterolemia / Mixed
NCT07674368 · ClinicalTrials.gov ↗ · ALK Fusion-positive Non-small Cell Lung Cancer
Phase 4 Not yet open 2026-07 China
Real-world First-line Serplulimab-based Immunochemotherapy for Extensive-stage Small Cell Lung Cancer
NCT06748495 · ClinicalTrials.gov ↗ · Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Observational Active, closed 2024-02 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Hunan Cancer Hospital trials

11 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Hunan Cancer Hospital trials

38 conditions
Breast Cancer2NSCLC (Non-small Cell Lung Carcinoma)1Stage III1EGFR Uncommon Mutations1Cancer Screening1Lung Cancer1Colorectal Cancer1Extensive-stage Small Cell Lung Cancer (ES-SCLC)1Cancer1FAP1Triple Negative Breast Neoplasms1Hepatocellular Carcinoma1HR+ Breast Cancer1Metastatic HER2 Negative Breast Carcinoma1Brain Metastases1Capecitabine1UDT11Gastric Cancer1Nasopharyngeal Carcinoma1Herpesvirus 4, Human1Stage IV (Metastatic) Breast Cancer1Nasopharyngeal Cancinoma (NPC)1Carcinoma, Non-Small-Cell Lung1Metastatic Breast Cancer1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China2017

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Breast Cancer

SponsorTrials
Fudan University48
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University21
Second Affiliated Hospital, Zhejiang University, School of Medicine19
AstraZeneca15
Shengjing Hospital15
Pfizer12
Sichuan Baili Pharmaceutical12
Cancer Institute and Hospital, Chinese Academy of Medical Sciences12
Hoffmann-La Roche10
Ruijin Hospital10

Sponsors with the most current trials registered for this condition.

06

Questions about Hunan Cancer Hospital trials

How many clinical trials does Hunan Cancer Hospital sponsor?

Hunan Cancer Hospital is the lead sponsor of 20 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Hunan Cancer Hospital trials recruiting?

Yes. 17 of its 20 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Hunan Cancer Hospital testing?

Its current trials name 11 drugs and biologicals as interventions. The most frequent are Utidelone (2), Anastrozole, Exemestane (1), Cadonilimab (1), Capecitabine (1) and Cisplatin (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.